Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus

Zai, Junjie; Yang, Kai; Xie, Lin; Zhu, Jiping; Feng, Xiaoting; Li, Yaoming

doi:10.1186/s13000-018-0773-1

Cited by 12 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sandwich immunoassay is a reliable tool for the rapid detection and mass screening of infectious viral antigens [ 30 , 31 ]. A SARS-CoV-2 S-ECD-specific sandwich immunoassay was developed using K104.1 and K104.2-HA as the capture and detection antibody, respectively.…”

Section: Resultsmentioning

confidence: 99%

Development and Characterization of Phage Display-Derived Monoclonal Antibodies to the S2 Domain of Spike Proteins of Wild-Type SARS-CoV-2 and Multiple Variants

Kim

Cho

Shin

et al. 2023

Viruses

View full text Add to dashboard Cite

The rapid emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has resulted in the ongoing global coronavirus disease 2019 (COVID-19) pandemic. Thus, the rapid development of a platform to detect a broad range of SARS-CoV-2 variants is essential for successful COVID-19 management. In this study, four SARS-CoV-2 spike protein-specific single-chain variable fragments (scFvs) were isolated from a synthetic antibody library using phage display technology. Following the conversion of these scFvs into monoclonal antibodies (mAbs) (K104.1–K104.4) and production and purification of the mAbs, the antibody pair (K104.1 and K104.2) that exhibited the highest binding affinity (K104.1 and K104.2, 1.3 nM and 1.9 nM) was selected. Biochemical analyses revealed that this antibody pair specifically bound to different sites on the S2 subunit of the spike protein. Furthermore, we developed a highly sensitive sandwich immunoassay using this antibody pair that accurately and quantitatively detected the spike proteins of wild-type SARS-CoV-2 and multiple variants, including Alpha, Beta, Gamma, Delta, Kappa, and Omicron, in the picomolar range. Conclusively, the novel phage display-derived mAbs we have developed may be useful for the rapid and efficient detection of the fast-evolving SARS-CoV-2.

show abstract

Section: Resultsmentioning

confidence: 99%

Development and Characterization of Phage Display-Derived Monoclonal Antibodies to the S2 Domain of Spike Proteins of Wild-Type SARS-CoV-2 and Multiple Variants

Kim

Cho

Shin

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Sandwich ELISA is a reliable and rapid detection tool for infectious viral antigens [ 35 , 36 ]. To establish a sandwich ELISA specific to wild-type SARS-CoV-2 RBD antigen, K102.1 was used as the capture antibody whereas K102.2-HA was used as the detection antibody.…”

Section: Resultsmentioning

confidence: 99%

Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2

Kim

Min²,

Lee³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in an ongoing global pandemic crisis, caused by the life-threatening illness coronavirus disease 2019 (COVID-19). Thus, the rapid development of monoclonal antibodies (mAbs) to cope with COVID-19 is urgently necessary. In this study, we used phage display to develop four human mAbs specific to the receptor-binding domain (RBD) of SARS-CoV-2. Our intensive in vitro functional analyses demonstrated that K102.1, an anti-SARS-CoV-2 RBD-specific mAb, exerted potent neutralizing activity against pseudoviral and live viral infection and the interaction between SARS-CoV-2 RBD and human angiotensin-converting enzyme 2. Monotherapy with K102.1 also revealed the therapeutic potential against SARS-CoV-2 infection in vivo. Further, this study developed a sandwich enzyme-linked immunosorbent assay with a non-competing mAb pair, K102.1 and K102.2, that accurately detected the RBDs of SARS-CoV-2 wild-type and variants with high sensitivity in the picomolar range. These findings suggest that the phage-display-based mAb selection from an established antibody library may be an effective strategy for the rapid development of mAbs against the constantly evolving SARS-CoV-2.

show abstract

“…The enzyme-linked immunosorbent assay (ELISA) is the gold standard for the detection of proteins, peptides, antibodies, and RNA/DNA of viruses because it has high sensitivity with a very low LOD and a high affinity for a surface epitope of viruses or bacteria [ 41 , 42 , 43 ]. However, commercial ELISA kits are relatively expensive and time-consuming (>120 min) [ 44 , 45 ].…”

Section: Virus Detection On Microfluidic Platformmentioning

confidence: 99%

Recent Advances in Molecular and Immunological Diagnostic Platform for Virus Detection: A Review

2023

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an ongoing coronavirus disease (COVID-19) outbreak and a rising demand for the development of accurate, timely, and cost-effective diagnostic tests for SARS-CoV-2 as well as other viral infections in general. Currently, traditional virus screening methods such as plate culturing and real-time PCR are considered the gold standard with accurate and sensitive results. However, these methods still require sophisticated equipment, trained personnel, and a long analysis time. Alternatively, with the integration of microfluidic and biosensor technologies, microfluidic-based biosensors offer the ability to perform sample preparation and simultaneous detection of many analyses in one platform. High sensitivity, accuracy, portability, low cost, high throughput, and real-time detection can be achieved using a single platform. This review presents recent advances in microfluidic-based biosensors from many works to demonstrate the advantages of merging the two technologies for sensing viruses. Different platforms for virus detection are classified into two main sections: immunoassays and molecular assays. Moreover, available commercial sensing tests are analyzed.

show abstract

Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus

Cited by 12 publications

References 27 publications

Development and Characterization of Phage Display-Derived Monoclonal Antibodies to the S2 Domain of Spike Proteins of Wild-Type SARS-CoV-2 and Multiple Variants

Development and Characterization of Phage Display-Derived Monoclonal Antibodies to the S2 Domain of Spike Proteins of Wild-Type SARS-CoV-2 and Multiple Variants

Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2

Recent Advances in Molecular and Immunological Diagnostic Platform for Virus Detection: A Review

Contact Info

Product

Resources

About